Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 29, 2026Insights into ImagingOpen Access

Combined MVO and IMH on CMR strongly predicts ~865% higher MACE risk.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does a CMR-based risk score integrating quantitative microvascular obstruction and intramyocardial hemorrhage improve prognostic evaluation for MACE in STEMI patients compared to established risk scores?

Population

568 STEMI patients who underwent PCI within 12 h of symptom onset, median age 61 years, 82% male, from a…

Comparison

Prognostic evaluation using a novel CMR-based… vs Established risk scores: GRACE score, Eitel CMR…

Design

Cohort, CMR images were analyzed independently by two radiologists blinded to…

Follow-up

median 3.1 years

Key result

The combination of microvascular obstruction > 1.06% LV and intramyocardial hemorrhage > 0.47% LV strongly predicted MACE (HR 9.646), and a risk score integrating these metrics achieved an AUC of 0.853.

Authors

XGXuefan GuTYTing-Xuan YinLYLing-Yi Yu

Discussion

Loading...

Member takes

Overview

MVO extent plus IMH may refine post-STEMI MACE risk stratification in observational data; leaves open prospective validation before guiding practice.

Key Points

  • To evaluate the prognostic value of combining quantitative microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH) extent assessed by cardiac magnetic resonance for predicting major adverse cardiovascular events (MACE) in STEMI patients.
  • Analyzed 568 STEMI patients in a retrospective multicenter study with a median follow-up of 3.1 years (IQR: 1.7–5.0 years).
  • Visualized MVO using late gadolinium enhancement and IMH using T2* mapping and T2-weighted CMR imaging.
  • Developed a prognostic risk score (Score 3) combining LVEF ≤ 45%, MVO > 1.06% LV, IMH > 0.47% LV, and the GRACE score, comparing it to established risk models.
  • Over the follow-up period, 108 patients (19%) developed MACE, with event rates rising progressively across risk categories from 8.8% to 58.3%.
  • The combination of MVO > 1.06% LV and IMH > 0.47% LV served as the strongest independent predictor of MACE (HR: 9.646, 95% CI: 6.327–14.705, p < 0.001).
  • Score 3 demonstrated superior predictive performance (AUC: 0.853) compared to the GRACE score (AUC: 0.748), Score 1 (AUC: 0.825), and Score 2 (AUC: 0.802).

Study Design

Type

Cohort (n=568)

Multicenter

Yes

Structured PICO

Does a CMR-based risk score integrating quantitative microvascular obstruction and intramyocardial hemorrhage improve prognostic evaluation for MACE in STEMI patients compared to established risk scores?

P
Population
568 STEMI patients who underwent percutaneous coronary intervention within 12 hours of symptom onset and had a cardiac magnetic resonance scan within 7 days, followed for a median of 3.1 years.
E
Exposure
Prognostic evaluation using a novel CMR-based risk score (Score 3) integrating GRACE score, LVEF ≤ 45%, quantitative microvascular obstruction (MVO > 1.06% LV), and intramyocardial hemorrhage (IMH > 0.47% LV).
C
Comparator
Established risk scores: GRACE score, Eitel CMR risk score (Score 1: GRACE, LVEF ≤47%, infarct size ≥19% LV, MVO > 1.4% LV), and Glasgow CMR risk score (Score 2: GRACE, LVEF ≤45%, presence of IMH).
O
Outcome
Major adverse cardiovascular events (MACE), defined as a composite of heart failure, all-cause death, reinfarction, and revascularization, at a median follow-up of 3.1 years.composite

Main Result

Hazard Ratio: 9.646 (95% CI 6.327–14.705)

Absolute Event Rate: 58.3% vs 8.8%

p-value: p=<0.001

Integrating quantitative CMR measurements of microvascular obstruction and intramyocardial hemorrhage into a clinical risk score significantly improves prognostic accuracy for MACE in STEMI patients following primary PCI.

Limitations

  • Retrospective design may introduce potential selection bias and unmeasured confounders
  • Cohort comprised only patients without contraindications to CMR and with complete clinical data for GRACE score calculation
  • Temporal differences in CMR image acquisition and variability in image quality across multiple centers may influence diagnostic accuracy
  • Lack of external validation in independent cohorts
  • T2* and T2WI sequences were limited to three-layer imaging, which may result in the underestimation of overall IMH measurements
  • Retrospective nature may introduce selection bias and unmeasured confounders
  • Cohort limited to patients without CMR contraindications and with complete GRACE data, which may limit generalizability
  • Temporal differences in CMR image acquisition and variability in image quality across multiple centers
  • Internal validation only; requires external validation in independent cohorts
  • T2* and T2WI sequences limited to three-layer imaging, potentially underestimating overall IMH measurements

Cite This Study

Gu et al. (2026) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=568). Extensive microvascular injury (MVO > 1.06% LV and IMH > 0.47% LV) vs. Limited microvascular injury (MVO ≤ 1.06% LV and IMH ≤ 0.47% LV) was evaluated on Major adverse cardiovascular events (MACE), defined as heart failure, all-cause death, reinfarction, and revascularization (HR 9.646, 95% CI 6.327-14.705, p=<0.001). The combination of microvascular obstruction > 1.06% LV and intramyocardial hemorrhage > 0.47% LV strongly predicted MACE (HR 9.646), and a risk score integrating these metrics achieved an AUC of 0.853.

synapsesocial.com/papers/6a92995f8e5d7d1fc0c114efhttps://doi.org/10.1186/s13244-026-02386-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global Burden of Cardiovascular Diseases and Risk Factors, 1990–20192020 · 11,698 citations
  2. 2Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials2017 · 468 citations